공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

디프테리아 : 파이프라인 리뷰

Diphtheria (Infectious Disease) - Drugs in Development, 2021

리서치사 Global Markets Direct
발행일 2021년 09월 상품 코드 213116
페이지 정보 영문 93 Pages
가격
US $ 2,000 ₩ 2,395,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,790,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,185,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


디프테리아 : 파이프라인 리뷰 Diphtheria (Infectious Disease) - Drugs in Development, 2021
발행일 : 2021년 09월 페이지 정보 : 영문 93 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

디프테리아는 세균성 감염증으로, 목·코의 점막으로부터 발병합니다. 만약 치료하지 않으면 신장 및 신경계, 심장이 심각한 손상을 입습니다. 주요 증상으로 목의 통증 및 쉰 목소리, 경부 림프절종창, 콧물, 발열·오한·권태감 등을 들 수 있습니다. 주요 치료법에는 항독소 및 항생제 등이 있습니다.

세계 각국에서의 디프테리아(Diphtheria) 치료용 파이프라인 제품 개발 상황에 대해 분석했으며, 제품 개발 및 출시 동향, 임상시험 각 단계 제품 리스트, 주요 기업 개요, 주요 약제 개요, 최신 업계 동향 등의 정보를 전해드립니다.

서론

  • 조사 범위

디프테리아 개요

치료제 개발

  • 파이프라인 제품 개요
  • 기업별 파이프라인
  • 대학/연구기관별 파이프라인 제품
  • 기업에서 개발중인 제품
  • 대학/연구기관에서 개발중인 제품

치료제 평가

  • 표적별
  • 투여 경로별
  • 분자 종류별

치료제 개발 참여 기업

  • Beijing Minhai Biotechnology Co Ltd
  • Biological E Ltd
  • Boryung Pharmaceutical Co Ltd
  • Daiichi-Sankyo
  • GlaxoSmithKline Plc
  • Green Cross Corp
  • Indian Immunologicals Ltd
  • Kaketsuken KK
  • LG Chem, Ltd.
  • Prometheon Pharma LLC
  • Sanofi
  • Sanofi Pasteur SA
  • Serum Institute of India Ltd
  • Shantha Biotechnics Ltd
  • Zydus Cadila Healthcare Ltd

약제 개요

디프테리아 : 휴지중인 프로젝트

디프테리아 : 개발이 중지된 제품

디프테리아 : 제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

LSH 17.06.30

List of Tables

List of Tables

  • Number of Products under Development for Diphtheria, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Companies, 2021 (Contd..1)
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Companies, 2021 (Contd..1)
  • Products under Development by Companies, 2021 (Contd..2)
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Diphtheria - Pipeline by AIM Vaccine Co Ltd, 2021
  • Diphtheria - Pipeline by Beijing Minhai Biotechnology Co Ltd, 2021
  • Diphtheria - Pipeline by Beijing Tiantan Biological Products Co Ltd, 2021
  • Diphtheria - Pipeline by Biken Co Ltd, 2021
  • Diphtheria - Pipeline by Biological E Ltd, 2021
  • Diphtheria - Pipeline by BioNet-Asia Co Ltd, 2021
  • Diphtheria - Pipeline by Boryung Pharmaceutical Co Ltd, 2021
  • Diphtheria - Pipeline by Cadila Healthcare Ltd, 2021
  • Diphtheria - Pipeline by CanSino Biologics Inc, 2021
  • Diphtheria - Pipeline by Changchun Bcht Biotechnology Co Ltd, 2021
  • Diphtheria - Pipeline by Chengdu Kanghua Biological Products Co Ltd, 2021
  • Diphtheria - Pipeline by Chongqing Zhifei Biological Products Co Ltd, 2021
  • Diphtheria - Pipeline by Emergent BioSolutions Inc, 2021
  • Diphtheria - Pipeline by GC Pharma, 2021
  • Diphtheria - Pipeline by GlaxoSmithKline Plc, 2021
  • Diphtheria - Pipeline by KM Biologics Co Ltd, 2021
  • Diphtheria - Pipeline by LG Chem Ltd, 2021
  • Diphtheria - Pipeline by Novo Medi Sciences Pvt Ltd, 2021
  • Diphtheria - Pipeline by Olymvax Biopharmaceuticals Inc, 2021
  • Diphtheria - Pipeline by Panacea Biotec Ltd, 2021
  • Diphtheria - Pipeline by Sanofi, 2021
  • Diphtheria - Pipeline by Serum Institute of India Pvt Ltd, 2021
  • Diphtheria - Pipeline by Shantha Biotechnics Pvt Ltd, 2021
  • Diphtheria - Pipeline by Suzhou Weichao Biotechnology Co Ltd, 2021
  • Diphtheria - Pipeline by VaxForm LLC, 2021
  • Diphtheria - Pipeline by Yisheng Biopharma Co Ltd, 2021
  • Diphtheria - Dormant Projects, 2021
  • Diphtheria - Dormant Projects, 2021 (Contd..1)
  • Diphtheria - Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development for Diphtheria, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Targets, 2021
  • Number of Products by Stage and Targets, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diphtheria - Drugs In Development, 2021, provides an overview of the Diphtheria (Infectious Disease) pipeline landscape.Diphtheria is a bacterial infection that affects the membranes of the throat and nose. If left untreated, diphtheria can cause severe damage to kidneys, nervous system, and heart. Symptoms include sore throat and hoarseness, swollen glands (enlarged lymph nodes) in neck, nasal discharge, fever and chills and malaise. Treatment includes antitoxins and antibiotics.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diphtheria - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Diphtheria (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Diphtheria (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Diphtheria and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 7, 4, 10, 1, 13, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Discovery stages comprises 1, 1 and 1 molecules, respectively.

Diphtheria (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Diphtheria (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Diphtheria (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Diphtheria (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Diphtheria (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Diphtheria (Infectious Disease)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Diphtheria (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Diphtheria (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Diphtheria - Overview
  • Diphtheria - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Diphtheria - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Diphtheria - Companies Involved in Therapeutics Development
  • AIM Vaccine Co Ltd
  • Beijing Minhai Biotechnology Co Ltd
  • Beijing Tiantan Biological Products Co Ltd
  • Biken Co Ltd
  • Biological E Ltd
  • BioNet-Asia Co Ltd
  • Boryung Pharmaceutical Co Ltd
  • Cadila Healthcare Ltd
  • CanSino Biologics Inc
  • Changchun Bcht Biotechnology Co Ltd
  • Chengdu Kanghua Biological Products Co Ltd
  • Chongqing Zhifei Biological Products Co Ltd
  • Emergent BioSolutions Inc
  • GC Pharma
  • GlaxoSmithKline Plc
  • KM Biologics Co Ltd
  • LG Chem Ltd
  • Novo Medi Sciences Pvt Ltd
  • Olymvax Biopharmaceuticals Inc
  • Panacea Biotec Ltd
  • Sanofi
  • Serum Institute of India Pvt Ltd
  • Shantha Biotechnics Pvt Ltd
  • Suzhou Weichao Biotechnology Co Ltd
  • VaxForm LLC
  • Yisheng Biopharma Co Ltd
  • Diphtheria - Drug Profiles
  • (diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis (acellular,adsorbed) + rotavirus + tetanus) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis + tetanus) (pentavalent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + haemophilus influenza [serotype B] + meningococcal + pertussis (acellular) + tetanus) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + haemophilus influenza [serotype B] + pertussis (acellular) + poliomyelitis + tetanus) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + tetanus) (tetravalent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (heptavalent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + Haemophilus influenzae [serotype B] + pertussis (acellular) + tetanus) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole cell) + polio + tetanus)(pentavalent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + haemophilus influenzae [serotype B] + pertussis (whole cell) + tetanus) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + pertussis (acellular) + tetanus) vaccine 1 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + pertussis (acellular) + tetanus) vaccine 1 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + pertussis (acellular) + tetanus) vaccine 2 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + pertussis (acellular) + tetanus) vaccine 2 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + pertussis (whole cell) + tetanus) (trivalent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + pertussis (whole cell) + tetanus) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + pertussis + poliomyelitis + tetanus) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + pertussis + tetanus) (acellular, adsorbed) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + pertussis + tetanus) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + pertussis + tetanus) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + tetanus + pertussis (acellular) + haemophilus influenzae [serotype B]) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + tetanus + pertussis (acellular) + poliomyelitis) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + tetanus + pertussis (acellular)) vaccine 1 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + tetanus + pertussis + poliomyelitis + haemophilus influenzae [serotype B]) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + tetanus) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Adacel plus - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • B-1004 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BK-1310 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • diphtheria antitoxin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • diphtheria vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • DTcP vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GC-3111A - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • KD-370 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LBVD - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • S-315 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Diphtheria - Dormant Projects
  • Diphtheria - Discontinued Products
  • Diphtheria - Product Development Milestones
  • Featured News & Press Releases
  • Mar 11, 2019: LG Chem gets $33.4 mil. from Gates Foundation for vaccine development
  • Nov 24, 2014: CanSinotech submitted CTA of "Diphtheria and Tetanus Toxoids and Component Pertussis Vaccine Adsorbed" to CFDA
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q